Showing results (221-230 of 241) with videos related to
Sort By:
Pageof 25
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.Cancer Research|October 21, 2016
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N Ingle, Fang Xie, Matthew J Ellis, et al.Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.Journal of the National Cancer Institute|July 2, 2013
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarkerDennis C Sgroi, Erin Carney, Elizabeth Zarrella, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.The New England Journal of Medicine|June 7, 2011
Exemestane for breast-cancer prevention in postmenopausal womenPaul E Goss, James N Ingle, José E Alés-Martínez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2010
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitorsJames N Ingle, Daniel J Schaid, Paul E Goss, et al.Pageof 25